Industry context
Sanofi [SNY]
Last Updated 24 Jun 2026 @ 16:00 (Exchange is closed)
Last: $41.33
-0.65%
-4.49
GaG Algo Score™
v1.0
Short
-4.49
Medium
-6.47
Long
-6.39
BUY
57.14%
return 2.18%
SELL
70.00%
return 16.32%
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 8.30% | 7.10% | 2.81% |
| Loss % | -8.99% | -5.68% | 5.15% |
| Duration | 23.0d | 12d | 33.9d |
| Total Pivots Found | 12 |
| Gain/Loss Legs | 11 (6 Gain / 5 Loss) |
| Last Pivot | Top @ $45.02 on 2026-06-05 |
| Change since Last Pivot | $-3.69 (-8.20%) |
Next Pivot Prediction Last: $41.33
| Predicted Next Type | Bottom |
| Predicted Price (Avg) | $40.97 |
| Predicted Price (Median) | $42.46 |
| Predicted Price Range (~68%) | $38.65 - $43.29 |
| Change to Avg Target | $-0.36 (-0.87%) |
| Predicted Date (Avg) | 2026-06-28 |
| Predicted Date Range (~68%) | 2026-05-25 - 2026-07-31 |
| Basis | Based on 5 historical losses (Avg: -8.99%, Median: -5.68%, StdDev of Abs: 5.15%) and duration (Avg: 23.0 days, StdDev: 33.9 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Sanofi lost modestly, down -0.65%.
Sanofi (SNY) stock price moved down modestly on Wednesday after the stock fell $-0.270 (-0.65%) from the previous session on above-average volume. The stock moved in line with the falling NASDAQ that fell -0.43%.(The stock has fallen 3 days straight.This prolonged decline suggests potential for a price bounce) With 7.69M shares traded, volume yesterday reached $317.67M. This was 3.17M shares less than the prior day. Compared to the 10-day average of 4.42M shares, volume was more than the average.
Sanofi signals
There is no conclusive signals given from RSI. The price is below both moving averages, and the short-term average is below the long-term average, confirming a sustained down-trend. Strong Bearish Consensus: A significant wave of negative pressure is evident across all time horizons. Technical indicators are decisively bearish in the short-term (20/30, net -56.7%), medium-term (20/30, net -56.7%), and long-term (20/30, net -56.7%), signaling a robust and sustained downtrend.
Sanofi Support & Resistance Levels
The stock is trading above the closest support level at $41.30. approximately $0.0300 (0.07%) away. This suggests it is currently acting as a floor, pushing down towards support.The sup dis das support s141.3 -
Sanofi Evaluation
- Short score: -4.49
- Medium score: -6.47
- Long score: -6.39
Relationship map
Correlation snapshot
<span style="background-color: lightgreen">Undervalued: <i class="arrow arrow-up"></i>0.74% <strong>$41.71</strong> paired level.</span>
Event context
Volume and dividends
Long volume corr.
0.02
Short volume corr.
-0.38
Positioning pressure
Short interest pressure
Short interest
0.28%
Of outstanding shares
Short float
0.31%
Of tradable float
Days to cover
2.83
Short interest divided by average volume
Squeeze probability
2.00%
+3.42% change
Short positioning does not currently stand out as a dominant risk factor.
Updated 2026-05-29Income profile
Dividend profile
Last Dividend
$2.42
2026-05-04
Next Dividend
$0
N/A
Avg. yearly yield
4.87%
Annually
Total paid
$39.90
27 payments
Sustainability
0
low (50.00%)
Growth potential
0
No dividend expected
Direction
0
Score based on dividend trend and payout behavior.
Yearly history
| Year | Dividend | Yield |
|---|---|---|
| - | $2.42 | 5.02% |
| - | $2.20 | 4.57% |
| - | $2.04 | 4.08% |
| - | $3.28 | 6.69% |
| - | $2.04 | 4.02% |
| - | $1.906 | 3.91% |
Recent payments
| Date | Dividend | Payment |
|---|---|---|
| 2026-05-04 | $2.42 | 2026-06-03 |
| 2025-05-09 | $2.20 | 2025-06-12 |
| 2024-05-09 | $2.04 | 2024-06-06 |
| 2023-05-30 | $1.903 | 2023-06-23 |
| 2023-05-25 | $1.380 | 2023-06-23 |
Earnings quality
Earnings history
Reported quarters
10
EPS beats
5
EPS misses
5
Avg. surprise
-5.35%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| ~2025 Q3? | 2025-10-24 | - | - | - | - |
| ~2025 Q2? | 2025-07-24 | - | $0.970 | - | - |
| ~2025 Q1? | 2025-04-24 | $0.940 | $0.900 | 4.44% | 11.63B |
| ~2024 Q4? | 2025-01-30 | $0.700 | $0.710 | -1.41% | 7.90B |
| ~2024 Q3? | 2024-10-25 | $1.570 | $1.350 | 16.30% | 14.16B |
| ~2024 Q2? | 2024-07-25 | $0.930 | $0.860 | 8.14% | 11.38B |
| ~2024 Q1? | 2024-04-25 | $0.970 | $0.940 | 3.19% | 11.12B |
| ~2023 Q4? | 2024-02-01 | $0.890 | $0.940 | -5.32% | 22.88B |
Analyst view
Analyst targets
Consensus
$51.00
Median
$51.00
Low
$50.00
High
$52.00
Recent target updates
News flow
Latest company news
Market coverage
zacks.com EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis Jun 23, 2026 wsj.com Sanofi Multiple Sclerosis Drug Gets EU Approval Jun 23, 2026 globenewswire.com Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Jun 23, 2026 zacks.com Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth? Jun 22, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers General
Currency
USD
Sanofi operates as a leading global pharmaceutical enterprise dedicated to the research development production and distribution of a wide array of therapeutic solutions across the United States Europe and numerous international markets The company strategically organizes its operations into three core divisions Pharmaceuticals Vaccines and Consumer Healthcare Within its Pharmaceutical segment Sanofi delivers specialized therapies including innovative human monoclonal antibodies addressing complex conditions like multiple sclerosis various neurological disorders immunology and inflammatory diseases oncology rare diseases and rare blood disorders This segment also encompasses treatments for diabetes cardiovascular health and established prescription medications Its Vaccine portfolio is extensive offering essential immunizations such as pediatric vaccines for poliomyelitis pertussis and Hib alongside influenza shots adult boosters meningitis vaccines and solutions for travel and endemic diseases The Consumer Healthcare division provides a broad spectrum of overthecounter products including remedies for allergies coughs and colds pain management liver support physical and mental wellness probiotics digestive health aids and nutritional supplements Additionally it offers various personal care items like daily body lotions antiitch creams moisturizing and soothing lotions body and foot creams and specialized powders for eczema Sanofi maintains a robust development pipeline with numerous pharmaceutical products and vaccines currently in various stages of research The company actively pursues strategic alliances exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid19 vaccine a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding and a collaboration and license option agreement with Prellis Biologics Inc Founded in 1973 and headquartered in Paris France the company was formerly known as SanofiAventis before officially changing its name to Sanofi in May 2011
Navigation